Raloxifene reduces triple-negative breast cancer tumor growth and decreases EGFR expression.

摘要: The poor prognosis of patients with triple-negative breast cancer (TNBC) and the lack targeted treatments have raised need for alternative therapies. Previous studies suggested an effect raloxifene, a selective estrogen receptor modulator that is independent (ER). Therefore, we assessed therapeutic value raloxifene in TNBC mouse models. Mice received daily oral treatment different doses raloxifene. Tumor progression was monitored weekly; addition microvessel density, proliferation, migration invasion, apoptosis tumorigenicity were analyzed. This study demonstrates (0.85 mg/kg) prevents tumor growth induces regression. treated tumors showed 54% decreased microvascular density proliferation 7-fold increase apoptosis. underlying mechanism associated 27-fold decrease expression epidermal factor (EGFR). Moreover, promoted translocation EGFR into endosomes cell migration, invasion vitro. Together, these data acts independently ER may be relevant as well control TNBC.